Valuation: Gain Therapeutics, Inc.

Market Cap 45.39M 41.13M 38.04M 34.33M 64.69M 4.28B 66.97M 457M 181M 2.29B 170M 167M 7.26B P/E 2026 *
-2.63x
P/E 2027 * -1.81x
Enterprise Value 45.39M 41.13M 38.04M 34.33M 64.69M 4.28B 66.97M 457M 181M 2.29B 170M 167M 7.26B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.81%
Yield 2026 *
-
Yield 2027 * -
1 day-3.70%
1 week+0.97%
Current month-7.96%
1 month-21.80%
3 months-50.94%
6 months-40.57%
Current year-67.70%
1 week 1.01
Extreme 1.01
1.18
1 month 0.94
Extreme 0.94015
1.34
Current year 0.94
Extreme 0.94015
3.29
1 year 0.94
Extreme 0.94015
4.34
3 years 0.89
Extreme 0.89
5.33
5 years 0.89
Extreme 0.89
9.5
10 years 0.89
Extreme 0.89
17.93
Manager TitleAgeSince
Chief Executive Officer 52 2024-06-24
Chief Tech/Sci/R&D Officer - 2024-03-24
Chief Tech/Sci/R&D Officer - 2020-08-31
Director TitleAgeSince
Chairman 70 2016-12-31
Director/Board Member 63 2019-04-30
Director/Board Member 58 2020-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Free

Director

25,000 0.0586%
7/15/26 Free

Founder

25,000 0.0586%
7/15/26 Free

Director

25,000 0.0586%
Change 5-day change 1-year change 3-year change Capi.($)
-3.70%+0.97%-63.25%-64.14% 45.39M
-2.69%-0.48%+53.97%+66.82% 66.33B
+0.41%+3.30%+11.31%+96.00% 60.62B
+1.23%+2.40%+25.18%+91.11% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
+3.28%-2.62%+80.46%+62.34% 32.22B
+2.62%+5.90%-37.29%+386.59% 26.58B
Average -0.10%+0.14%+27.33%+153.55% 41B
Weighted average by Cap. -0.02%+0.20%+37.12%+153.33%

Financials

2026 *2027 *
Net sales - -
Net income -17.08M -15.47M -14.31M -12.91M -24.34M -1.61B -25.19M -172M -68.17M -860M -64.08M -62.72M -2.73B -28.83M -26.12M -24.16M -21.8M -41.08M -2.72B -42.53M -290M -115M -1.45B -108M -106M -4.61B
Net Debt - -
Projected Income Statement - Annual - Gain Therapeutics, Inc.
Logo Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Employees
-
Date Price Change Volume
26-11-13 US$1.040 -3.70% 328,879
26-11-12 US$1.080 -2.70% 300,382
26-11-11 US$1.110 +2.78% 292,767
26-11-10 US$1.080 -0.92% 411,687
26-11-09 US$1.090 +5.83% 309,671
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Gain Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.040USD
Average target price
6.600USD
Spread / Average Target
+534.62%
  1. Stock Market
  2. Stocks
  3. GANX Stock